Appointments: Changes at SOTIO, Helsinn, Sobi, AMRI, Blade and Vertex
The latest biopharma industry appointments include a new chairman at Bone Therapeutics, chief executives at SOTIO and Helsinn Therapeutics, new CFOs at Sobi, AMRI and at Blade Therapeutics, and a new CMO at Vertex Pharmaceuticals.
You may also be interested in...
Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.